Join us on April 2nd from 1:00-2:00 pm eastern (10:00-11:00 am pacific, 12:00-1:00 pm central) for a webinar exploring a clinical trial in hairy cell leukemia (HCL).
Dr. Jae Park from Memorial Sloan Kettering Cancer Center will discuss his study comparing Vemurafenib and Obinutuzumab to Cladribine and Rituximab in previously untreated HCL patients. Following his presentation, there will be moderated Q&A.
This webinar is part of the HCLF's Clinical Trials webinar series. Through this series, we hope to educate our patient network about current HCL trials, empower patients with options, and raise awareness of the impact of HCLF-funded research. Learn about this and other clinical trials on the HCLF website: www.hairycellleukemia.org/clinicaltrials